Expansion of Excelyte manufacturing plant completed at Midland

NewsGuard 100/100 Score

Integrated Environmental Technologies, Ltd. (OTCBB: IEVM) announces that Benchmark Performance Group, Inc., its exclusive worldwide distributor serving the oil and gas industry, has completed the expansion of its Excelyte® manufacturing plant at its Midland, Texas facility. This expansion has significantly increased capacity over its original plant capabilities.

Benchmark markets IEVM’s EcaFlo® Anolyte under the registered trade name, Excelyte®. EcaFlo® Anolyte received its EPA product registration on August 18, 2008 and is the only environmentally responsible biocide of its kind. Excelyte® has seen a significant increase in market demand; therefore, a number of other Excelyte® expansions are planned for Benchmark’s seven (7) other manufacturing facilities throughout the United States.

Wayne Kinsey, President and CEO of Benchmark, stated, “Recently, we’ve seen a significant, growing demand for Excelyte®. While this growth started for us in the oil and gas industry, we’ve seen a number of new applications for Excelyte® that include the hospital and medical industries, professional sports, schools and universities, and grocery store chains.” Excelyte® has been proven effective against scores of bacterial and viral pathogens, i.e. H1N1 (“swine flu”), methicillin-resistant staphylococcus aureus (“MRSA”), E. coli and Salmonella.

IEVM’s President and CEO, Bill Prince, commented, “As a valued industry partner, Benchmark has invested a great deal of time, energy, money and other resources in developing markets for Excelyte®. We look forward to continuing to work together with Benchmark well into the future as we move Excelyte® forward in all markets and application areas.”

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson and CureVac collaborate on mRNA-based cancer vaccines